ICYMI: ? CSL Behring Shuttering #Pasadena Facility ? Anixa Biosciences, Inc. Moves Onto Third Cohort in Trial for #OvarianCancer CER-T Have a #celltherapy or #genetherapy update you’d like to share? Tag us with #AroundTheHelix! https://lnkd.in/eFEK57Sg
CGTLive
在线音视频媒体
Cranbury，New Jersey 2,943 位关注者
CGTLive? delivers the latest news and expert insights on cell, gene, regenerative, and engineered medicines.
关于我们
CGTLive? delivers quality and relevant information to healthcare professionals on cell, gene, regenerative, and engineered medicines to ultimately improve care.
- 网站
-
https://www.cgtlive.com/
CGTLive的外部链接
- 所属行业
- 在线音视频媒体
- 规模
- 501-1,000 人
- 总部
- Cranbury，New Jersey
- 类型
- 私人持股
地点
-
主要
获取路线
2 Clarke Dr
US，New Jersey，Cranbury，08512
CGTLive员工
动态
-
ICYMI: The explosion of early-stage #CRISPR research has fueled a demand for novel drug-delivery vectors to help improve the specificity and efficiency of #geneediting. #genetherapy Read more: https://lnkd.in/eYrptZyM
Improving Cell and Gene Therapy with Innovative Nonviral Delivery Vectors
cgtlive.com
-
In honor of #WorldPancreaticCancerDay, held on the third Thursday of November each year, CGTLive? is taking a look back at progress for #celltherapy and #genetherapy candidates in #PancreaticCancer over the past year. #PancreaticCancerAwareness More: https://lnkd.in/eFQHqPpG
-
ICYMI: Adicet Bio, Inc noted that it expects to announce initial data from patients with #LupusNephritis in the first half of 2025. #Lupus #celltherapy Read more: https://lnkd.in/eStcmDQP
First Patient Dosed in Trial for Adicet's T-Cell Therapy ADI-100 in Autoimmune Disease
cgtlive.com
-
? CSL Behring Shuttering #Pasadena Facility ? Anixa Biosciences, Inc. Moves Onto Third Cohort in Trial for #OvarianCancer CER-T Have a #celltherapy or #genetherapy update you’d like to share? Tag us with #AroundTheHelix! https://lnkd.in/eFEK57Sg
Around the Helix: Cell and Gene Therapy Company Updates – November 20, 2024
cgtlive.com
-
ICYMI: The FDA’s IND clearance allows for the geographic expansion of the phase 1b trial, which has previously been cleared in Italy and France, to the United States. #MuscularDystrophy #genetherapy #LimbGirdleMuscularDystrophy Atamyo Therapeutics Read more: https://lnkd.in/esw7X8b7
Atamyo Therapeutics' Gene Therapy ATA-200 Cleared for US Trial in LGMD Type 2C/R5
cgtlive.com
-
ICYMI: The study’s efficacy findings covered 26 patients who had confirmed CD70-positive #RenalCellCarcinoma and were evaluable as of the October 14, 2024 data cutoff. #celltherapy #CART Allogene Therapeutics Read more: https://lnkd.in/eF5_Fcnj
Allogene’s CAR-T ALLO-316 Demonstrates Ability to Produce Responses in Renal Cell Carcinoma, but Safety Data Includes 3 On-Study Deaths
cgtlive.com
-
Adicet Bio, Inc noted that it expects to announce initial data from patients with #LupusNephritis in the first half of 2025. #Lupus #celltherapy Read more: https://lnkd.in/eStcmDQP
First Patient Dosed in Trial for Adicet's T-Cell Therapy ADI-100 in Autoimmune Disease
cgtlive.com
-
ICYMI: Dholaria spoke about the safety and efficacy results, highlighting the nonoccurrence of graft versus host disease in the treated patients and the 91% ORR in the enhanced lymphodepletion arm. Poseida Therapeutics, Inc. #mmsm #MultipleMyeloma #celltherapy Watch: https://lnkd.in/eXCF_GcC
Bhagirathbhai R. Dholaria, MD, on Evaluating Allogeneic CAR-T P-BCMA-ALLO1 in R/R Multiple Myeloma
cgtlive.com
-
The FDA’s IND clearance allows for the geographic expansion of the phase 1b trial, which has previously been cleared in Italy and France, to the United States. #MuscularDystrophy #genetherapy #LimbGirdleMuscularDystrophy Atamyo Therapeutics Read more: https://lnkd.in/esw7X8b7
Atamyo Therapeutics' Gene Therapy ATA-200 Cleared for US Trial in LGMD Type 2C/R5
cgtlive.com